C-Rad AB (publ)

Research C-Rad AB (publ) (CRAD-B) on Bullrun: valuation model: 15.9% undervalued, market cap SEK 1.23B, P/E 42.3, dividend yield 0.3%. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerCRAD-B
ExchangeST
CountrySweden
SectorHealthcare
IndustryMedical Devices
CurrencySEK
Valuation signal15.9% undervalued
Market capSEK 1.23B
P/E42.3
Dividend yield0.3%
Financial periodFY2024
RevenueSEK 469.00M
Revenue growth10.5%
Net incomeSEK 56.45M
Free cash flowSEK 29.21M
Gross margin67.6%

Valuation Snapshot

Bullrun's latest valuation model marks C-Rad AB (publ) as 15.9% undervalued; latest market cap is SEK 1.23B; P/E is 42.3; dividend yield is 0.3%.

About C-Rad AB (publ)

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility;

Frequently asked questions

Is C-Rad AB (publ) overvalued or undervalued?

Bullrun's valuation model currently marks C-Rad AB (publ) as 15.9% undervalued.

What is C-Rad AB (publ)'s market cap?

C-Rad AB (publ)'s market capitalization is SEK 1.23B.

What is C-Rad AB (publ)'s P/E ratio?

C-Rad AB (publ)'s price-to-earnings (P/E) ratio is 42.3.

Does C-Rad AB (publ) pay a dividend?

C-Rad AB (publ) has a dividend yield of 0.3%.